Browsing by title
Now showing items 2485-2504 of 4698
-
Late recurrence in ER+ breast cancer - refining risk prediction beyond 5 years
(Institute of Cancer Research (University Of London), 2021-11-30)ER positive (ER+) breast cancer has the potential to recur many years following diagnosis. Predicting who is most at risk of recurrence and when this may occur is complex. Risk prediction incorporates clinical, pathological ... -
Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways.
(AMER ASSOC CANCER RESEARCH, 2023-06-02)UNLABELLED: Understanding the evolutionary pathways to metastasis and resistance to immune-checkpoint inhibitors (ICI) in melanoma is critical for improving outcomes. Here, we present the most comprehensive intrapatient ... -
Latest Advances in the Use of Therapeutic Focused Ultrasound in the Treatment of Pancreatic Cancer.
(MDPI, 2022-01-27)Traditional oncological interventions have failed to improve survival for pancreatic cancer patients significantly. Novel treatment modalities able to release cancer-specific antigens, render immunologically "cold" pancreatic ... -
Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial.
(FERRATA STORTI FOUNDATION, 2021-07-01)The optimal way to use immunomodulatory drugs as components of induction and maintenance therapy for multiple myeloma is unresolved. We addressed this question in a large phase III randomized trial, Myeloma XI. Patients ... -
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
(ELSEVIER SCIENCE INC, 2019-01-01)BACKGROUND: Patients with multiple myeloma treated with lenalidomide maintenance therapy have improved progression-free survival, primarily following autologous stem-cell transplantation. A beneficial effect of lenalidomide ... -
Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial.
(FERRATA STORTI FOUNDATION, 2020-12-01) -
Length of FMR1 repeat alleles within the normal range does not substantially affect the risk of early menopause.
(OXFORD UNIV PRESS, 2016-10-01)STUDY QUESTION: Is the length of FMR1 repeat alleles within the normal range associated with the risk of early menopause? SUMMARY ANSWER: The length of repeat alleles within the normal range does not substantially affect ... -
Lenvatinib for use in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy.
(2017-03)Introduction In patients with mRCC options for second line therapies, following progression on anti-angiogenic agents, that demonstrate a survival advantage in clinical trials have been limited. Recently a number of agents ... -
Leonidas D. Marinelli: Cold War Scientist.
(RADIATION RESEARCH SOC, 2023-02-01) -
Leveraging Genome and Phenome-Wide Association Studies to Investigate Genetic Risk of Acute Lymphoblastic Leukemia.
(AMER ASSOC CANCER RESEARCH, 2020-08-01)BACKGROUND: Genome-wide association studies (GWAS) of childhood cancers remain limited, highlighting the need for novel analytic strategies. We describe a hybrid GWAS and phenome-wide association study (PheWAS) approach ... -
Leveraging Human Genetics to Guide Cancer Drug Development.
(AMER SOC CLINICAL ONCOLOGY, 2018-11-21)PURPOSE: The high attrition rate of cancer drug development programs is a barrier to realizing the promise of precision oncology. We have examined whether the genetic insights from genome-wide association studies of cancer ... -
Leveraging multi-layer imager detector design to improve low-dose performance for megavoltage cone-beam computed tomography.
(IOP PUBLISHING LTD, 2018-01-30)While megavoltage cone-beam computed tomography (CBCT) using an electronic portal imaging device (EPID) provides many advantages over kilovoltage (kV) CBCT, clinical adoption is limited by its high doses. Multi-layer imager ... -
Life After COVID-19 for Cancer Clinical Trials.
(ELSEVIER SCIENCE INC, 2020-10-01) -
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.
(2021-05-12)Purpose Effective treatment options are limited for patients with advanced (metastatic or unresectable) melanoma who progress after immune checkpoint inhibitors and targeted therapies. Adoptive cell therapy using ... -
Lights and Shadows in Immuno-Oncology Drug Development.
(MDPI, 2021-02-09)The rapidly evolving landscape of immuno-oncology (IO) is redefining the treatment of a number of cancer types. IO treatments are becoming increasingly complex, with different types of drugs emerging beyond checkpoint ... -
Line focus x-ray tubes-a new concept to produce high brilliance x-rays.
(IOP PUBLISHING LTD, 2017-10-27)Currently hard coherent x-ray radiation at high photon fluxes can only be produced with large and expensive radiation sources, such as 3[Formula: see text] generation synchrotrons. Especially in medicine, this limitation ... -
Lineage tracing in human tissues.
(WILEY, 2022-05-05)The dynamical process of cell division that underpins homeostasis in the human body cannot be directly observed in vivo, but instead is measurable from the pattern of somatic genetic or epigenetic mutations that accrue in ...